Loading clinical trials...
Loading clinical trials...
Interaction Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics of Single Doses of 0.5 and 1 mg of BAY 63-2521 in Patients With PAH and Stable Treatment of Sildenafil 20 mg TID in a Non-randomized, Non-blinded Design
Conditions
Interventions
Riociguat (Adempas, BAY63-2521)
Locations
5
Germany
Heidelberg, Baden-Wurttemberg, Germany
Löwenstein, Baden-Wurttemberg, Germany
Giessen, Hesse, Germany
Greifswald, Mecklenburg-Vorpommern, Germany
Dresden, Saxony, Germany
Start Date
October 1, 2008
Primary Completion Date
August 1, 2009
Completion Date
November 1, 2009
Last Updated
December 16, 2015
NCT07079592
NCT05719415
NCT07039604
NCT03388476
NCT01065454
NCT04732221
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions